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ABSTRACT
TERT (telomerase reverse transcriptase) is the catalytic component of telomerase. 
TERT shows little expression in normal somatic cells but is commonly re-expressed in 
cancers, facilitating immortalization. Recently-discovered TERT promoter mutations 
create binding sites for ETS-family transcription factors to upregulate TERT. ETS1 is 
reported to be important for TERT upregulation in melanoma. However it is unclear 
when in melanoma progression TERT and ETS1 proteins are expressed. To elucidate 
this question, ETS1 and TERT immunohistochemistry were performed on a panel 
of benign (n=27) and dysplastic nevi (n=34), radial growth phase (n=29), vertical 
growth phase (n=25) and metastatic melanomas (n=27). Lesions were scored by 
percentage of positive cells. ETS1 was readily detectable in all lesions, but not in 
normal melanocytes. TERT was located in either the nucleolus, the nucleoplasm (non-
nucleolar) or both. Non-nucleolar TERT increased in prevalence with progression, 
from 19% of benign nevi to 78% of metastases. It did not however correlate with 
cell proliferation (Ki-67 immunostaining), nor differ significantly in prevalence 
between primary melanomas with or without a TERT promoter mutation. These 
results demonstrate that ETS1 is expressed very early in melanoma progression, and 
interestingly only non-nucleolar TERT correlates clearly in prevalence with melanoma 
progression. It can be acquired at various stages and by mechanisms other than 
promoter mutations.
INTRODUCTION
One of the proposed hallmarks of cancer cells is 
immortality: the ability to proliferate indefinitely by 
bypassing cell senescence [1]. Cell senescence is a stable 
proliferative arrest following extensive cell division and 
telomere attrition, or other triggers including oncogene 
overexpression or genotoxic stresses [2]. Senescence can 
be triggered by short, dysfunctional telomeres, through 
DNA-damage signaling. In the germline and some stem 
cells, replicative senescence is prevented through telomere 
maintenance by active telomerase. TERT (telomerase 
reverse transcriptase), the catalytic component of 
telomerase, is transcriptionally repressed in normal adult 
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somatic cells, which thus do senesce; but is reportedly 
re-expressed in 85-90% of human cancers, permitting 
immortality [3]. This re-expression seems to play a central 
role in carcinogenesis, making TERT and telomerase 
potentially important as drivers and therapeutic targets.
Benign and malignant primary pigmented lesions 
can be classified histologically into four main types with 
increasing malignancy, namely benign/banal melanocytic 
nevi, dysplastic nevi, thin, early melanomas termed 
radial growth phase (RGP) melanomas, and thicker, 
invasive or vertical growth phase (VGP) melanomas [4]. 
These types show progressively more genetic changes, 
disrupting characteristic molecular pathways, notably 
senescence, as reviewed in [5]. A benign nevus consists 
of a clonal mass of melanocytes that have senesced after 
proliferation triggered by an oncogenic mutation, usually 
in BRAF or NRAS, activating the MAPK pathway [6-10]. 
The cell-cycle inhibitor CDKN2A (isoform 1), hereafter 
called by its common name p16, appears the primary 
effector of senescence in melanocytes [11, 12], and is 
commonly expressed strongly in nevi [6, 7]. CDKN2A is 
a frequent site of mutations in familial melanoma [5-7]. 
Mutations or epigenetic disruption of the p16 pathway 
appear increasingly through the series, dysplastic nevi, 
RGP and VGP melanoma [7, 9]. VGP melanomas also 
tend to accumulate mutations suppressing apoptosis, 
Figure 1: ETS1 expression with melanoma progression. (A) Percentage of lesions showing high (>50% cells) (black) and 
moderate (5-50%) prevalence (grey). Prevalence <5% was not reproducibly distinguished from 0 by independent observers and thus had 
uncertain significance [25]; not shown. BN: benign nevus (n=10); DN: dysplastic nevus (n=10); RGP (n=8); VGP (n=9); METS: metastatic 
melanoma samples (n=9). (B) Representative highly prevalent ETS1 immunostaining in a benign nevus and VGP melanoma, with parallel 
MART1 IHC to show position of lesional cells. (C) ETS1 and MART1 double IHC in normal skin. Epidermal normal melanocytes express 
cytoplasmic MART1 (red) but no nuclear ETS1 (brown); expanded in inset. A group of lymphoid cells in the dermis (brown nuclei) 
provides a positive ETS1 control. Scale bars: 100 μm.
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discussed elsewhere [13, 5]. p16 deficiency contributes 
to senescence bypass, but telomere extension is also 
essential. Functional tests indicate that immortality 
emerges only late in melanoma progression [13]. Average 
telomerase activity rises strongly in later progression 
[14, 15]. Much interest was generated by recent findings 
that this rise is commonly mediated through mutations at 
hotspots in the TERT promoter, creating binding sites for 
ETS-family transcription factors [16-18] and facilitating 
TERT transcription [19]. Such mutations appear much 
more common in metastatic than primary melanomas 
[16, 20], yet are also detected in some early lesions 
intermediate between nevi and melanomas [9], and also 
(rarely) in the germline of some melanoma-prone families 
[16, 18].
Little is understood of TERT protein expression in 
relation to these mutations and to progression. Availability 
of a reliable anti-TERT antibody [21] has enabled us to 
investigate this by TERT immunohistochemistry (IHC) 
in nevi and melanomas. ETS1 expression was also re-
examined. ETS1 has been implicated as a predominant 
factor activating mutant TERT promoters in melanoma 
[19], but previous studies have reached differing 
conclusions on ETS1 expression relative to melanoma 
progression [22-24].
RESULTS
Role of antigen-retrieval pH; revisiting p16 
expression in melanoma progression
Antigen retrieval for IHC is commonly done at 
pH 6. However optimization tests showed strongest 
immunostaining after retrieval at pH 9, for all antibodies 
used here (Supplementary Figures 1-4). Retrieval at pH 9 
was therefore used throughout this study.
For comparison with TERT expression, we re-
examined p16 immunostaining, also to test whether the 
strong staining would increase apparent prevalence, as 
p16 is detected heterogeneously in nevi [6, 7]. However, 
while more cells were positive, the results (Supplementary 
Figure 5) were comparable to those reported before [25, 
27-29], strengthening evidence that p16 expression is 
heterogeneous in many nevi and absent from most VGP 
melanomas.
ETS1 expression with melanoma progression
Nuclear ETS1 was expressed extensively and 
strongly in all lesions at all five tested stages of 
progression, except for a few metastases (Figure 1A, 1B). 
To compare normal melanocytes in vivo we examined 
Figure 2: TERT expression and localization with melanoma progression. Abbreviations and bar color coding as in Figure 1. BN 
(n=27), DN (n=34), RGP (n=29), VGP (n=25) and METS (n=27). (A) Total TERT prevalence, showing a borderline trend with progression 
(p=0.054). (B) Nucleolar TERT in a benign nevus nest (brown granules are melanin). (C, D) Non-nucleolar TERT in melanomas, diffuse 
in nucleoplasm (arrows) or in punctate nuclear foci (arrowheads). Scale bars: 50 μm. (E) Nucleolar TERT prevalence, showing no trend 
with progression (p=0.41). (F) Non-nucleolar TERT prevalence, showing a highly significant rise with progression (p=0.006). Significance 
testing was by χ2 tests.
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normal epidermis in benign nevus sections. No ETS1 
was detected. To test normal melanocytes specifically, 
double immunohistochemistry was performed on normal 
human skin for ETS1 and the melanosomal protein 
MART1 (MLANA) (Figure 1C). Epidermal melanocytes, 
identified by cytoplasmic MART1, were confirmed 
negative for nuclear ETS1. Thus, in melanocytes in 
vivo, ETS1 expression appears to be activated upon 
nevogenesis.
TERT expression with melanoma progression: 
nucleolar and non-nucleolar
TERT levels in the various lesional types are shown 
in Figure 2A. There was a numerical positive trend in 
total TERT prevalence, but with borderline statistical 
significance (p=0.0545). Benign and dysplastic nevi 
often displayed surprisingly widespread TERT positivity.
However, it was noticed that subcellular TERT 
location varied between lesions. In benign nevi TERT 
was typically localized solely to the nucleolus (Figure 
2B). However in melanomas the protein was often 
found in distinct subnuclear foci, or diffusely across the 
nucleus (Figure 2C, 2D), designated ‘non-nucleolar’. 
Lesions were then recounted, discriminating nucleolar 
and non-nucleolar TERT (Figure 2E, 2F). There was 
no trend for nucleolar expression (p=0.41), but a 
statistically highly significant positive trend for non-
nucleolar TERT detection with melanoma progression 
(p=0.006).
Non-nucleolar TERT was typically present 
heterogeneously, in 5-50% of cells within a lesion (grey 
areas, Figure 2F). It was found in less than 20% of 
benign nevi, in 40-50% of dysplastic nevi and primary 
melanomas, but in nearly 80% of metastatic samples. 
Prevalence differed significantly between benign nevi 
and all other lesions combined (p=0.004); also between 
metastatic melanomas and all other lesions combined 
(p=0.001). Taken together, these results suggest that gain 
of non-nucleolar TERT occurs in a few benign nevi, in 
some dysplastic nevi, but most commonly at the transition 
to metastasis.
To ensure specificity, TERT peptide blocking was 
performed, on two lesions with exclusively nucleolar 
(Supplementary Figure 6A), and predominantly non-
nucleolar immunostaining respectively (Supplementary 
Figure 6B). Nuclear TERT detection was greatly reduced 
or absent in both cases, supporting high antibody 
specificity and that the antigen in both subnuclear 
locations is indeed TERT.
Figure 3: Ki-67 expression and lack of association with non-nucleolar TERT. (A) Ki-67 prevalence, highly significantly rising 
with melanoma progression (p<0.0001, χ2 test). Abbreviations and bar color coding as in Figure 1. BN (n=10), DN (n=10), RGP (n=8), VGP 
(n=9) and METS (n=10). (B) Grouped scatter plot illustrating poor agreement between Ki-67 and non-nucleolar TERT prevalence (κ=0.15). 
The area of each circle is proportional to the number of lesions with the indicated prevalence for each marker. (C) Examples of lesions 
displaying poor agreement. Top: highly prevalent TERT but no Ki-67 expression. Bottom: widespread Ki-67 but very little non-nucleolar 
(although much nucleolar) TERT expression. Arrows: melanophages (macrophages which have engulfed melanin). Scale bars: 50 μm.
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Non-nucleolar TERT does not associate with cellular 
proliferation
Hypothesizing that non-nucleolar TERT might be 
linked to immortalization, we tested whether its presence 
correlated with proliferation, by immunostaining adjacent 
sections for proliferative marker Ki-67.
Ki-67 expression was well correlated with 
melanoma progression (p<0.0001), as expected [30]. 
Expression was rare in nevi but common in primary 
melanomas; nearly all metastases were >50% positive 
(Figure 3A). There was poor statistical agreement however 
between Ki-67 and non-nucleolar TERT in individual 
lesions (Figure 3B; κ=0.15). Examples of divergence 
between Ki-67 and TERT are shown in Figure 3C. Still, all 
lesions with >50% cells positive for non-nucleolar TERT, 
and most of those with 5-50%, were also Ki-67 positive. 
Figure 4: TERT expression in primary melanomas with and without a TERT promoter mutation. No significant difference 
was observed between primary melanomas with (n=27) or without a TERT promoter mutation (n=28), for (A) total TERT (p=0.59), (B) 
nucleolar TERT (p=0.62) or (C) non-nucleolar TERT (p=0.45), by χ2 tests. Bar color coding as in Figure 1.
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The lack of correlation was attributable to frequent lesions 
with Ki-67 but no/rare (<5%) non-nucleolar TERT.
Non-nucleolar TERT expression does not 
associate with TERT promoter mutation status in 
primary melanomas
Since prevalence of both non-nucleolar TERT 
and TERT promoter mutations correlate with melanoma 
progression, we investigated whether non-nucleolar 
TERT might be a marker for these mutations. Primary 
melanomas with known TERT mutation status were now 
also analyzed by TERT IHC.
No significant differences were found however 
between melanomas with or without a TERT promoter 
mutation, in either total (p=0.59, Figure 4A), nucleolar 
(p=0.60, Figure 4B), or non-nucleolar TERT detection 
(p=0.45, Figure 4C). These results indicate that TERT can 
Figure 5: TERT colocalization with nucleolin, not coilin, in cultured human melanoma cells and melanocytes. A375P 
is an immortal melanoma line, Hermes 3A cells are immortalized melanocytes and SGML-2 is a diploid adult melanocyte strain. All cells 
were proliferating. Panels show double immunofluorescence for TERT (red) with nucleolin or Cajal body marker coilin (green). Nuclei 
visualized with DAPI (blue). Scale bars: 5 μm. TERT localized to nucleoli, not Cajal bodies, in all cells in these cultures.
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also be upregulated in melanoma through mechanisms 
other than promoter mutations.
Nucleolar TERT location in cultured melanocytic 
cells
We next investigated TERT via immunocytochemistry 
in melanocytic cell cultures, to compare normal and 
malignant cells and test the hypothesis that non-nucleolar 
TERT might indicate cell immortality. We used A375P 
melanoma cells, Hermes 3A TERT/CDK4-immortalized 
human melanocytes [7], and SGML-2 normal human 
melanocytes. Cells were also immunostained for nucleolar 
marker nucleolin, and for coilin, a marker of Cajal bodies, a 
reported site of telomerase assembly [31].
Interestingly, in all three cell lines TERT was 
present and localized entirely to nucleoli (Figure 5). No 
co-localization was observed with coilin, indicating TERT 
is not (or only very transiently) found in Cajal bodies in 
these cells. The finding also seemed inconsistent with 
non-nucleolar TERT as an indicator of immortality. We 
tested whether the nucleolar location here might be an 
artefact of fixation, given TERT’s high isoelectric point 
(~11.3) [32] and hence positive charge at near-neutral 
pH. The nucleolus (rich in negatively charged RNA) 
has been reported to accumulate positively charged 
proteins [33]. Cells were therefore now fixed at pH 10 
to neutralize TERT. No change in TERT location was 
observed however (Supplementary Figure 7), suggesting 
it was not artefactual. The expression of TERT in non-
immortal melanocytes in culture but not in vivo remains 
unexplained, and these data indicate no simple link 
between non-nucleolar TERT and immortality or active 
telomerase.
DISCUSSION
ETS1 expression was detected in all nevi and but 
not in normal epidermal melanocytes, agreeing with [24] 
but not with [23]. This upregulation may occur because 
nevi are senescent; ETS1 upregulation was reported 
in senescent fibroblasts [34]. It may also be because 
nevi carry an activated oncogene, activating ETS1 by 
phosphorylation downstream of RAS/RAF/MAPK 
signaling [5], and possibly increasing its abundance. 
At any rate, this presence of ETS1 could allow TERT 
expression in a nevus cell acquiring an oncogenic TERT 
promoter mutation, since these mutations reportedly 
associate with increased TERT transcription and protein 
expression, in the presence of ETS-family factors 
[20, 35]. This would activate telomerase, potentially 
impairing senescence stability and being clonally 
selective.
TERT immunostaining has not to our knowledge 
previously been analyzed as nucleolar or non-nucleolar 
relative to melanoma progression. We found that 
only non-nucleolar TERT increased significantly in 
prevalence with melanoma progression. Benign nevi had 
predominantly nucleolar TERT, aligning with a report 
that nucleolar TERT is not functional [36]. However the 
“melanoma-like” non-nucleolar TERT was also found 
in 20% of benign nevi, and 40% of dysplastic nevi. 
TERT promoter mutations have also been detected as 
an early event in some “intermediate” (dysplastic-like) 
lesions [9], indicating remarkably that active telomerase 
may be selective even within a largely senescent tissue. 
Dysplastic nevi were estimated to transform very rarely 
into melanoma (~1 in 30,000) [37], implying that the 
non-nucleolar TERT seen here in about 40% of dysplastic 
lesions is not sufficient for immortality. This conforms 
with the finding that some p16 mutations apparently arise 
only after TERT promoter mutations [9]. One wonders 
how such TERT mutations can become clonally expanded, 
in a nevus with unmutated p16. Perhaps in these cases one 
or both p16 copies are silenced by methylation, or TERT 
allows some repair of telomeric DNA damage even during 
arrest, and this reduces p16 activation.
No significant difference in TERT protein expression 
was observed between primary melanomas with or without 
a mutated TERT promoter; thus IHC cannot be used as an 
assay for the presence of the mutation, as has been hoped. 
This initially seemed surprising, but findings were similar 
in recent studies of glioblastoma [38] and a previous report 
on melanoma [39] (although without stated validation of 
their antibody, which gave strong cytoplasmic staining). 
Evidently TERT expression can be activated by mechanisms 
other than mutation. For example, Fan et al [40] reported a 
positive correlation between multiple cytosine methylation 
in part of the TERT promoter (667-482 bp upstream of the 
ATG start site) and TERT expression, in melanomas arising 
from congenital nevi or lacking a TERT promoter mutation. 
They cited similar previous findings in brain tumors. 
Conversely, the -146 C>T TERT promoter mutation has 
been reported to require non-canonical NF- κB signaling 
to co-operate with ETS1 [41]. Thus lesions carrying this 
mutation but negative for TERT protein may lack this 
signaling, or another co-operating factor. Moreover it was 
recently reported that these promoter mutations alone lead 
to low levels of TERT mRNA expression, below detection 
limits and insufficient for maintenance of all telomeres, 
so that additional changes seem to be needed for further 
upregulation and cell immortalization [42], consistent with 
the present data.
Nucleolar TERT expression did not alter with 
melanoma progression. The nucleolus was reported 
as a site of telomerase assembly, from where it would 
relocate to telomeres during DNA replication [31, 43]. 
This might predict a correlation of non-nucleolar TERT 
immunostaining with cell proliferation (Ki-67 prevalence), 
which we therefore tested for, but did not see, suggesting 
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additional reasons for extranucleolar location. Others 
have suggested that the nucleolus regulates telomerase 
activity. Transfection of exogenous TERT into various 
malignant cells gave a pan-nuclear localization (i.e. 
including non-nucleolar), but in normal diploid fibroblasts 
it localized solely to the nucleolus [36, 44-46]. These 
results suggest dysregulation of TERT localization in 
malignant cells. Nucleolin and PINX1 are reportedly both 
required for localizing TERT to the nucleolus [44, 46]. We 
reported increasing nucleolin expression with melanoma 
progression [25], which does not readily explain the 
trend for TERT; however we know of no data on PINX1 
expression in melanoma.
In summary, we report strong ETS1 expression 
in all nevi and melanomas but not normal melanocytes, 
providing a mechanism for how early TERT promoter 
mutations can be selective following oncogene activation. 
We also report for the first time a pathologically significant 
aspect of TERT localization relative to the nucleolus: 
only non-nucleolar TERT increases in prevalence with 
melanoma progression. It will be important to investigate 
in future the mechanism and significance of this non-
nucleolar location, which did not seem to be linked 
directly to cellular immortality, at least in our cell cultures. 
No significant difference in TERT expression or location 
was observed between primary melanomas with or 
without a TERT promoter mutation, consistent with the 
conclusion that TERT upregulation is more important for 
the development of a melanoma than the mechanism of 
upregulation.
MATERIALS AND METHODS
Patients and specimens
This study was approved by the West London and 
GTAC Research Ethics Committee (ref. 08/H0803/154). 
Samples were obtained from patients at St George’s 
Hospital, with written consent. A total of 142 lesional 
samples were used for TERT IHC: 27 benign nevi, 34 
dysplastic nevi, 29 RGP melanomas, 25 VGP melanomas 
and 27 metastatic melanomas. Smaller numbers of lesions 
were available for IHC of other proteins (see figure 
legends). Blinded samples of primary melanomas with 
a wild-type (n=28) or mutated TERT promoter (n=27) 
were sent to London from the Biobank of the Instituto 
Valenciano de Oncología. Samples were obtained from 
patients at the Institute with written consent.
Immunohistochemistry
Detailed protocols for immunohistochemistry 
and peptide-blocking are given in the Supplementary 
Materials. Sections were examined by microscope 
and classed as containing either <5%, 5-50% or >50% 
positive lesional cells, a system giving high agreement 
between two independent scorers [25]. All specimens were 
evaluated by two scorers. Where scores did differ, lesions 
were re-examined jointly to reach agreement. Statistical 
analyses, using GraphPad Prism version 6.07, were χ2 tests 
for significance of differences between categories and a 
kappa test for concordant immunostaining of two proteins. 
p<0.05 was considered significant.
Cell cultures
A375P melanoma cells and Hermes 3A immortal 
human melanocytes were from the Wellcome Trust 
Functional Genomics Cell Bank at St George’s. Cell 
Bank cultures are validated by IDEXX Bioresearch and 
were grown by us for less than 6 months from recovery 
of cryopreserved stocks. SGML-2 was a normal adult 
epidermal melanocyte strain explanted at St George’s 
from an abdominoplasty; cells were cultured as 
described [26].
Double immunofluorescence
Cells were grown on glass coverslips in 16-mm 
wells, washed twice in PBSD (complete Dulbecco’s PBS 
with CaCl2 and MgCl2) and fixed in 4% paraformaldehyde 
in PBSD for 20 minutes. After two washes in PBSD, cells 
were permeabilized with 0.1% Triton X-100 in PBSD 
for 4 minutes. Three washes in PBSD were carried out 
before blocking in 10 mg/ml BSA in PBSD. Cells were 
left overnight in primary antibody diluted in 10 mg/ml 
BSA in PBSD, at 4OC in a humidified chamber. Primary 
antibodies used were against TERT (EST21-A, Alpha 
Diagnostic International, 1:500), coilin (ab87913, Abcam, 
1:1000) and nucleolin (ab136649, Abcam, 1:2000). After 
five brief washes with PBSD, cells were incubated in 
Alexa Fluor 594-conjugated goat anti-rabbit IgG (A-
11012, Life Technologies, 1:400) for detection of TERT 
and Alexa Fluor 488-conjugated goat anti-mouse IgG (A-
11008, Life Technologies, 1:400) for nucleolin or coilin. 
After 3 washes in PBSD, cells were counterstained with 
1 μg/ml DAPI for 10 min, washed 3x in PBSD and once 
in dH2O, then mounted on slides in Citifluor. A LSM 510 
Zeiss confocal microscope and ZEN 2009 software (Zeiss) 
were used to capture images.
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